Vertex Pharmaceuticals (Ireland) Limited
SpainAll drugs from this manufacturer
-
It is used to help lung cells function better in patients with cystic fibrosis (CF) who have at least one CFTR gene mutation that responds to treatment. It helps improve breathing and lung function and may facilitate weight gain.
Dosage form: tablets, film-coated
Active substance Dosage ivacaftor 37,5 mg tezacaftor 25 mg elexacaftor 50 mg -
It helps lung cells function better in some patients with cystic fibrosis (CF), improving breathing and helping to make weight gain easier.
Dosage form: granules, in sachet
Active substance Dosage ivacaftor 60 mg tezacaftor 40 mg elexacaftor 80 mg -
It is used to help lung cells function better in patients with cystic fibrosis (CF) who have at least one CFTR gene mutation that responds to the medication.
Dosage form: tablets, film-coated
Active substance Dosage tezacaftor 50 mg ivacaftor 75 mg elexacaftor 100 mg -
It is used to help lung cells function better in some patients with cystic fibrosis (CF) who have at least one mutation in the CFTR gene that responds to the medication.
Dosage form: granules, in sachet
Active substance Dosage ivacaftor 75 mg tezacaftor 50 mg elexacaftor 100 mg -
It is used to treat patients with cystic fibrosis (CF) who have specific mutations in the CFTR gene. It helps abnormal proteins function better to improve chloride movement in the cells.
Dosage form: tablets, film-coated
Active substance Dosage ivacaftor 150 mg -
It is used to treat infants and children (from 4 months of age onwards) with cystic fibrosis who have certain specific mutations in the CFTR gene. It can be used alone or in combination with other medications depending on age and the type of mutation.
Dosage form: granules
Active substance Dosage ivacaftor 25 mg -
It is used for the treatment of infants and children with cystic fibrosis (CF) who have certain specific mutations in the CFTR gene. It can be used alone or in combination with other medications depending on age and the type of mutation.
Dosage form: granules, in sachet
Active substance Dosage ivacaftor 50 mg -
It is used to treat infants and children with cystic fibrosis (CF) who have certain specific mutations in the CFTR gene. It can be used alone or in combination with other medications depending on age and the type of mutation.
Dosage form: granules
Active substance Dosage ivacaftor 59,5 mg -
It is used to treat patients with cystic fibrosis (CF) who have certain specific mutations in the CFTR gene, either as a standalone treatment or in combination with other medications.
Dosage form: tablets, film-coated
Active substance Dosage ivacaftor 93,75 mg -
It is used for the treatment of infants and children with cystic fibrosis (CF) who have certain specific mutations in the CFTR gene. It can be used alone or in combination with other medications depending on age and mutation.
Dosage form: granules, in sachet
Active substance Dosage ivacaftor 75 mg -
It is used for the long-term treatment of cystic fibrosis (CF) in patients 6 years of age or older who have a specific mutation called F508del in the CFTR gene.
Dosage form: tablets, film-coated
Active substance Dosage lumacaftor 100 mg ivacaftor 125 mg -
It is used for the long-term treatment of cystic fibrosis (CF) in patients 1 year of age or older who have a specific mutation called F508del in the CFTR gene.
Dosage form: granules
Active substance Dosage lumacaftor 100 mg ivacaftor 125 mg -
It is used for the long-term treatment of cystic fibrosis (CF) in patients 1 year of age or older who have a specific mutation called F508del in the CFTR gene.
Dosage form: granules
Active substance Dosage lumacaftor 150 mg ivacaftor 188 mg -
It is used for the long-term treatment of cystic fibrosis (CF) in patients 6 years of age and older who have a specific mutation called F508del in the CFTR gene.
Dosage form: tablets, film-coated
Active substance Dosage ivacaftor 125 mg lumacaftor 200 mg -
It is used for the long-term treatment of cystic fibrosis (CF) in patients 1 year of age or older who have a specific mutation called F508del in the CFTR gene.
Dosage form: granules
Active substance Dosage lumacaftor 75 mg ivacaftor 94 mg -
It is used for the long-term treatment of patients aged 6 years or older with cystic fibrosis (CF) who have certain genetic mutations. It helps improve lung function and may facilitate weight gain.
Dosage form: tablets, film-coated
Active substance Dosage tezacaftor 100 mg ivacaftor 150 mg -
It is used for the long-term treatment of patients aged 6 years or older with cystic fibrosis (CF) who have certain genetic mutations. It helps improve lung function and may facilitate weight gain.
Dosage form: tablets, film-coated
Active substance Dosage tezacaftor 50 mg ivacaftor 75 mg